UBS Group
CALC icon

UBS Group’s CalciMedica CALC Stock Holding History

UBS Group’s Portfolio CALC Stock Details CALC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16 Sell
16
-1
-6% -$1 ﹤0.01% 10296
2026
Q1 		$9 Sell
17
-1,083
-98% -$2.2K ﹤0.01% 10341
2025
Q4 		$7.25K Buy
1,100
+1,083
+6,371% +$4.22K ﹤0.01% 8462
2025
Q3 		$52 Sell
17
-16,986
-100% -$48.9K ﹤0.01% 10016
2025
Q2 		$27.2K Buy
17,003
+16,783
+7,629% +$28.8K ﹤0.01% 8231
2025
Q1 		$421 Sell
220
-105
-32% -$262 ﹤0.01% 9785
2024
Q4 		$1.15K Buy
325
+310
+2,067% +$1.09K ﹤0.01% 9300
2024
Q3 		$66 Hold
15
– – ﹤0.01% 9207
2024
Q2 		$59 Sell
15
-1
-6% -$5 ﹤0.01% 9220
2024
Q1 		$66 Buy
16
+2
+14% +$9 ﹤0.01% 8892
2023
Q4 		$40 Sell
14
-422
-97% -$1.22K ﹤0.01% 9013
2023
Q3 		$1.16K Buy
436
+422
+3,014% +$1.4K ﹤0.01% 8071
2023
Q2 		$56 Buy
+14
New +$61 ﹤0.01% 8589
2023
Q1 		– Sell
-384
Closed -$2.69K – 9643
2022
Q4 		$2.69K Buy
384
+369
+2,460% +$4.14K ﹤0.01% 9637
2022
Q3 		$0 Sell
15
-1,127
-99% -$16K ﹤0.01% 10362
2022
Q2 		$17K Buy
1,142
+610
+115% +$8.33K ﹤0.01% 7082
2022
Q1 		$9K Buy
532
+318
+149% +$6.06K ﹤0.01% 8532
2021
Q4 		$5K Buy
214
+199
+1,327% +$7.73K ﹤0.01% 9377
2021
Q3 		$1K Hold
15
– – ﹤0.01% 9150
2021
Q2 		$1K Sell
15
-132
-90% -$8.66K ﹤0.01% 9128
2021
Q1 		$11K Buy
147
+54
+58% +$16.2K ﹤0.01% 7848
2020
Q4 		$38K Buy
93
+70
+304% +$20.7K ﹤0.01% 6417
2020
Q3 		$4K Buy
+23
New +$4.79K ﹤0.01% 7392

Other funds holding CALC

LGM
L1 Global Manager Melbourne $142M AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

UBS Group's CALC Position: Q2 2026 in Review

UBS Group reduced its CalciMedica (CALC) stake by 5.9% in Q2 2026, selling an estimated $1 and leaving 16 shares worth $16. The position accounts for ﹤0.01% of the portfolio, ranked #10296.

UBS Group first reported a position in CALC in Q3 2020 and has held it in 23 quarters since. The position peaked at $38K in Q4 2020. 19 funds tracked by Wall St. Rank hold CALC as of Q2 2026.

  • UBS Group held 16 shares of CalciMedica worth $16 as of Q2 2026.
  • UBS Group sold 1 CalciMedica share in Q2 2026, an estimated $1.
  • CalciMedica made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10296 holding.
  • UBS Group first reported a position in CalciMedica in Q3 2020 and has held it in 23 quarters since.
  • UBS Group's CalciMedica position peaked at $38K in Q4 2020.
  • 19 funds tracked by Wall St. Rank held CalciMedica as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.